ep beat strong opex management guid tweak higher better fear
quick take offer solid despit slight weaken revenu ep beat opex
manag compani turn rais fy guid revenu broadli touch soft better
fear strength larg custom specialti continu turn margin touch better
although gp line strong cost manag drove om beat distribut actual flat y-o-
move line lost nickel vs model tax pick back penni share
count thu entireti ep beat oper natur manag carri beat forward rais
fy guid may point less beat howev mind good enough lastli
ytd quit strong track net incom convers all-in solid given
recent mix perform would expect share higher
revenu revenu growth quarter came weaker prior qs expect like given prior pharmaci
neutral distribut rev grew vs estimate due strength abc largest
custom robust specialti sale overal market growth
neg revenue grew y-o-i estimate driven growth canada world courier
mwi
industri color read thru suppli chain abc abil come in-lin rev despit tough recent
quarter biggest custom bode well distributor next week especi given cvss retail
margin modestli better although gp essenti line opex mm drove
om beat segment
slight headwind tax off-set modest benefit lower share count
ep convers ep beat entir oper convers remain notabl strong
guidanc color rais fy ep rang like better expect
evercor isi grate consider ross muken healthcar
distribut institut investor all-america research poll
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
click link like confer call focu dial-in
impact revenu growth chain pharmaci pre-buy ahead inflat
topic cc
updat pharmedium challeng timelin address fda concern
thought ohio opioid trial progress upcom litig spend
detail threat brand busi model given part rebat chang
chang gener deflation/brand inflat environ
date/tim may et
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti resumpt independ price war result materi margin degrad
signific profit pressur signific downtick sell-sid gener deflat without similar movement buy side margin
result overal compress increment soft pharmedium growth lessen inflat continu challeng
relat revamp qc process polit threat chang rx price methodolog gross net intens scrutini
opioid curtail distribut profit execut challeng onboard hd smith asset potenti leakag key
independ custom transit period inabl transit specialti contract long term new econom
allow fair payment differenti servic
articl articl
time dissemin may
analyst elizabeth anderson suzi yoon ross muken primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
report approv and/or distribut evercor group llc evercor group licens broker-deal regul
industri regulatori author finra intern strategi invest group uk limit lsi uk authoris
regul unit kingdom financi conduct author institut sale trade research busi evercor group
lsi uk collect oper global market brand name evercor lsi evercor lsi evercor group lsi uk
subsidiari evercor partner inc evercor partner trademark logo servic mark shown report regist
trademark evercor partner
analyst associ respons prepar report receiv compens base variou factor includ evercor partner
total revenu portion gener affili invest bank transact evercor lsi seek updat research
appropri variou regul may prevent happen certain instanc asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgment
evercor lsi gener prohibit analyst associ member household maintain financi interest secur
compani analyst area coverag except polici requir specif approv member complianc
depart ownership subject complianc applic regul disclosur evercor lsi also prohibit analyst associ
member household serv offic director advisori board member employe compani analyst
report may includ tactic call describ near-term event catalyst affect subject compani market overal
expect short-term price impact equiti share subject compani tactic call separ analyst
long-term recommend outperform under-perform reflect stock forward expect return formal rate
may differ target price recommend reflect analyst long-term view
applic current disclosur regard subject compani cover report avail offic evercor lsi
